Literature DB >> 24300880

Gastrointestinal cancer: targeted therapies in gastric cancer-the dawn of a new era.

Manish A Shah1.   

Abstract

The international phase III REGARD study demonstrated improved overall survival with ramucirumab as second-line therapy for patients with advanced-stage gastric and gastroesophageal junction adenocarcinoma. As a novel biological treatment, is ramucirumab also the harbinger of a new era of targeted therapies in this prevalent and highly morbid disease?

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24300880     DOI： 10.1038/nrclinonc.2013.231

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


  8 in total

1.  THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION.

Authors:  P LAUREN
Journal:  Acta Pathol Microbiol Scand       Date:  1965

2.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Authors:  Yung-Jue Bang; Eric Van Cutsem; Andrea Feyereislova; Hyun C Chung; Lin Shen; Akira Sawaki; Florian Lordick; Atsushi Ohtsu; Yasushi Omuro; Taroh Satoh; Giuseppe Aprile; Evgeny Kulikov; Julie Hill; Michaela Lehle; Josef Rüschoff; Yoon-Koo Kang
Journal:  Lancet       Date:  2010-08-19       Impact factor: 79.321

3.  Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy.

Authors:  Iain Beehuat Tan; Tatiana Ivanova; Kiat Hon Lim; Chee Wee Ong; Niantao Deng; Julian Lee; Sze Huey Tan; Jeanie Wu; Ming Hui Lee; Chia Huey Ooi; Sun Young Rha; Wai Keong Wong; Alex Boussioutas; Khay Guan Yeoh; Jimmy So; Wei Peng Yong; Akira Tsuburaya; Heike Grabsch; Han Chong Toh; Steven Rozen; Jae Ho Cheong; Sung Hoon Noh; Wei Kiat Wan; Jaffer A Ajani; Ju-Seog Lee; Manuel Salto Tellez; Patrick Tan
Journal:  Gastroenterology       Date:  2011-04-28       Impact factor: 22.682

4.  Global cancer statistics.

Authors:  Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman
Journal:  CA Cancer J Clin       Date:  2011-02-04       Impact factor: 508.702

5.  Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.

Authors:  Atsushi Ohtsu; Manish A Shah; Eric Van Cutsem; Sun Young Rha; Akira Sawaki; Sook Ryun Park; Ho Yeong Lim; Yasuhide Yamada; Jian Wu; Bernd Langer; Michal Starnawski; Yoon-Koo Kang
Journal:  J Clin Oncol       Date:  2011-08-15       Impact factor: 44.544

6.  Molecular classification of gastric cancer: a new paradigm.

Authors:  Manish A Shah; Raya Khanin; Laura Tang; Yelena Y Janjigian; David S Klimstra; Hans Gerdes; David P Kelsen
Journal:  Clin Cancer Res       Date:  2011-03-23       Impact factor: 12.531

7.  Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.

Authors:  Charles S Fuchs; Jiri Tomasek; Cho Jae Yong; Filip Dumitru; Rodolfo Passalacqua; Chanchal Goswami; Howard Safran; Lucas Vieira Dos Santos; Giuseppe Aprile; David R Ferry; Bohuslav Melichar; Mustapha Tehfe; Eldar Topuzov; John Raymond Zalcberg; Ian Chau; William Campbell; Choondal Sivanandan; Joanna Pikiel; Minori Koshiji; Yanzhi Hsu; Astra M Liepa; Ling Gao; Jonathan D Schwartz; Josep Tabernero
Journal:  Lancet       Date:  2013-10-03       Impact factor: 79.321

8.  Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial.

Authors:  Eric Van Cutsem; Sanne de Haas; Yoon-Koo Kang; Atsushi Ohtsu; Niall C Tebbutt; Jian Ming Xu; Wei Peng Yong; Bernd Langer; Paul Delmar; Stefan J Scherer; Manish A Shah
Journal:  J Clin Oncol       Date:  2012-05-07       Impact factor: 44.544
  8 in total
  21 in total

1.  DCT015, a new sorafenib derivate, inhibits tumor growth and angiogenesis in gastric cancer models.

Authors:  Wenyan Wang; Hui Wang; Yingying Ni; Zhenming Yao; Liang Ye; Jingwei Tian
Journal:  Tumour Biol       Date:  2016-01-15

2.  PCAF acts as a gastric cancer suppressor through a novel PCAF-p16-CDK4 axis.

Authors:  Hong-Jun Fei; Li-Dong Zu; Jun Wu; Xiao-Shu Jiang; Jing-Long Wang; Y Eugene Chin; Guo-Hui Fu
Journal:  Am J Cancer Res       Date:  2016-12-01       Impact factor: 6.166

3.  Gastric cancer drug trials - are women second class citizens?

Authors:  Lishi Wang; Yan Jiao; Yun Jiao; Yanhong Cao; Weikuan Gu
Journal:  Nat Rev Clin Oncol       Date:  2014-06-03       Impact factor: 66.675

4.  Gastric cancer drug trials - are women second class citizens?

Authors:  Manish A Shah
Journal:  Nat Rev Clin Oncol       Date:  2014-06-03       Impact factor: 66.675

Review 5.  Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.

Authors:  Erika Vacchelli; Jonathan Pol; Norma Bloy; Alexander Eggermont; Isabelle Cremer; Wolf Hervé Fridman; Jérôme Galon; Aurélien Marabelle; Holbrook Kohrt; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-02-03       Impact factor: 8.110

6.  LncRNA PINK1-AS promotes Gαi1-driven gastric cancer tumorigenesis by sponging microRNA-200a.

Authors:  Yan Lv; Yin Wang; Yu Song; Shu-Sheng Wang; Kai-Wen Cheng; Zhi-Qing Zhang; Jin Yao; Li-Na Zhou; Zhuo-Yan Ling; Cong Cao
Journal:  Oncogene       Date:  2021-05-06       Impact factor: 9.867

7.  Circular RNA ITCH suppresses metastasis of gastric cancer via regulating miR-199a-5p/Klotho axis.

Authors:  Yan Wang; Huiting Wang; Ruiqi Zheng; Peipei Wu; Zixuan Sun; Jingyan Chen; Leilei Zhang; Chenxiao Zhang; Hui Qian; Jiajia Jiang; Wenrong Xu
Journal:  Cell Cycle       Date:  2021-01-27       Impact factor: 4.534

8.  Long intergenic noncoding RNA00265 promotes proliferation of gastric cancer via the microRNA-144-3p/Chromobox 4 axis.

Authors:  Zengxi Yang; Xi OuYang; Liang Zheng; Lizhen Dai; Wenjuan Luo
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

9.  Anticancer activity of TTAC-0001, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR-2/KDR) monoclonal antibody, is associated with inhibition of tumor angiogenesis.

Authors:  Dong Geon Kim; Younggeon Jin; Juyoun Jin; Heekyoung Yang; Kyeung Min Joo; Weon Sup Lee; Sang Ryeol Shim; Sung-Woo Kim; Jinsang Yoo; Sang Hoon Lee; Jin-San Yoo; Do-Hyun Nam
Journal:  MAbs       Date:  2015-09-01       Impact factor: 5.857

Review 10.  Evolution of Gastric Cancer Treatment: From the Golden Age of Surgery to an Era of Precision Medicine.

Authors:  Yoon Young Choi; Sung Hoon Noh; Jae-Ho Cheong
Journal:  Yonsei Med J       Date:  2015-09       Impact factor: 2.759
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.